The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Programmed death protein 1 (PD1) is a common immunosuppressive member on the
surface of T cells and plays an imperative part in downregulating the immune system and …

Myocarditis is an inflammatory disease of the heart that may occur because of infections,
immune system activation, or exposure to drugs. The diagnosis of myocarditis has changed …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

A review of cancer immunotherapy: from the past, to the present, to the future Page 1 S87
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …

Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers.
Consistent basic data suggest that these same checkpoints are critical negative regulators of …

Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection
of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position …